Where the stock stands
Aster DM Healthcare Ltd., a Healthcare sector company, closed at 814.9 on 13 July 2026, with a marginal 0.04 percent gain from the previous session. The stock trades 2.58 percent below its 52-week high of 836.5 and 56.98 percent above its 52-week low of 519.1. Over the past year, it has delivered a 31.13 percent return, with the bulk of that coming in the last three months — a 19.31 percent advance. The shorter-term picture is flatter: the one-month return sits at essentially zero (-0.006 percent), while the one-week gain is 2.95 percent. The market capitalisation stands at 71,311 crore. Valuation metrics show a price-to-earnings ratio of 108.07, price-to-book of 9.23, and return on equity of 10.1 percent. The dividend yield is 0.49 percent.
What the smart-money flow shows
The evidence pack contains no data on futures and options positioning, no named bulk or block deals, no institutional holding changes or streaks, and no insider trading filings. This absence is material: without F&O data, one cannot assess whether open interest is building or unwinding, or whether the recent price action is accompanied by long buildup (fresh futures positions opened as the price rose) or short covering. Similarly, the lack of disclosed bulk deals means there is no visibility into whether large operators are accumulating or distributing shares. The data shows no recent insider filings, so no inference can be drawn about management confidence or concern through their personal transactions. For a stock that has rallied sharply over three months, this information gap is notable — investors relying on smart-money signals have no direct read on positioning.
The technical picture
The stock sits above both its 50-day and 200-day simple moving averages, a constructive posture that typically reflects intermediate and longer-term momentum. However, there is no golden cross (the 50-day average crossing above the 200-day) or death cross in place. The 14-day RSI reads 63.0, neither overbought nor oversold. Relative volume at 1.09 indicates trading activity roughly in line with recent averages. The proximity to the 52-week high — within 2.6 percent — suggests the stock is testing a key resistance zone established at 836.5. The one-month flat return against a strong three-month rally indicates a consolidation phase after the sharp advance from the May-June period.
Catalysts and what to watch
The dominant theme in recent exchange filings is the completion of Aster DM Healthcare's merger with Quality Care India Limited (QCIL). According to NSE filings dated 3-4 July and 13-14 July 2026, the company has informed the exchange about the "successful completion of the merger" and subsequent allotment of equity shares to QCIL shareholders pursuant to the amalgamation scheme. These filings carry a bullish bias tag in the data. Offsetting this, the same period saw two filings — on 3 and 4 July — regarding the resignation of a Director/KMP/SMP, tagged bearish. No further details on the resignation are provided. News headlines from Business Standard, CNBC TV18, The Economic Times and others appear in the pack, but these are dated 28 to 138 days ago and do not alter the immediate picture. What the data establishes is a post-merger integration phase with a recent governance change; what it does not establish is how the merged entity's financials will trend, whether institutional flows are supporting the price, or how derivatives positioning might amplify or dampen moves from current levels.